Welcome to our dedicated page for Bioatla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on Bioatla stock.
BioAtla, Inc. (BCAB) is a clinical-stage biopharmaceutical innovator advancing conditionally active biologic therapies for cancer treatment. This news hub provides investors and industry professionals with essential updates on the company’s proprietary CAB technology platform, clinical trial progress, and strategic developments.
Access timely press releases covering key milestones including regulatory filings, partnership announcements, and financial results. Our curated collection features updates on antibody-drug conjugate trials, intellectual property expansions, and operational developments across BioAtla’s global facilities.
This resource serves as your primary source for tracking BCAB’s progress in developing tumor-selective therapies. Bookmark this page for direct access to verified corporate communications and objective reporting on clinical advancements. Check regularly for updates on pipeline candidates and business strategy execution.
BioAtla (Nasdaq: BCAB) entered agreements providing flexible financing totaling up to $22.5 million to support operations while finalizing a strategic partnership. BioAtla received a $7.125 million gross cash advance under Pre-paid Advance Agreements for $7.5 million face value, which accrues 4% interest and may be repaid in cash or converted into common stock at the lower of $1.39 or 95% of the lowest daily VWAP during a specified look-back. Yorkville committed up to $15 million under a Standby Equity Purchase Agreement to buy common stock at a 3% discount over three years if the company exercises its option. Tungsten Advisors acted as placement agent.
BioAtla (Nasdaq: BCAB) reported Q3 2025 results and clinical updates on Nov 13, 2025. The company achieved FDA alignment on a planned randomized Phase 3 Oz-V trial in 2L+ OPSCC with dual primary endpoints (overall response rate and overall survival) and potential accelerated approval. BA3182 (CAB-EpCAM x CAB-CD3-TCE) dose escalation showed a confirmed partial response ongoing >6 months and a Phase 1 readout is expected in H1 2026. Mecbotamab vedotin (Mec-V) showed median OS 21.5 months in 44 evaluable soft tissue sarcoma patients. Q3 results: R&D $9.5M, G&A $4.2M, net loss $15.8M, cash $8.3M and a recent $2.0M milestone payment.
BioAtla (Nasdaq: BCAB) reported that mecbotamab vedotin (Mec-V), an AXL-targeting CAB ADC, achieved a median overall survival (OS) of 21.5 months in a 44-patient subset with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma, versus ~12 months with approved agents.
Data (cutoff March 25, 2025) show median OS 22.9 months in the combination arm and 18.4 months in monotherapy; 12-month OS rate 73%; disease control rate 52%; two partial responses reported. Safety was manageable with no treatment-related deaths; grade 3/4 neutropenia 21% and transaminase elevations 16%.
BioAtla (Nasdaq: BCAB) will announce its third quarter 2025 financial results and provide business highlights on Thursday, November 13, 2025. The company will host a conference call and webcast at 4:30 p.m. ET to discuss results for the quarter ended September 30, 2025. Investors can access the live webcast via the company website and dial in domestically at (800) 343-4136 or internationally at (203) 518-9843 using Conference ID BIOATLA.
The press release with financial results will be posted in News Releases prior to the call, and a replay will be available under Events & Presentations in the Investors section of the website.
BioAtla (NASDAQ: BCAB) will present a poster at the International Papillomavirus Society Conference in Bangkok (Oct 23–26, 2025) detailing mechanistic rationale and clinical data for its ADC ozuriftamab vedotin (Oz-V) targeting ROR2 in advanced HPV+ oropharyngeal squamous cell carcinoma (OPSCC). The poster, titled “Targeting HPV E6/E7 Upregulation of the Transmembrane Receptor Tyrosine Kinase ROR2 with the ADC Ozuriftamab Vedotin in Patients with Advanced HPV+ Oropharyngeal Squamous Cell Carcinoma,” will be presented on Oct 25, 2025 during E-Poster 02 (6:30–8:00 PM ICT). The presentation provides a molecular review of CAB-ROR2-ADC, discusses ROR2 expression linked to HPV infection, and highlights clinical data previously shown at medical congresses. Presentation materials will be posted in the company’s Publications section at www.bioatla.com after the session concludes.
BioAtla (Nasdaq: BCAB) reported preliminary Phase 1 results for BA3182, a dual‑conditionally binding EpCAM x CD3 bispecific T‑cell engager, presented at ESMO 2025 (Oct 19, 2025). In a 35‑patient, heavily pretreated cohort (median 3 prior lines), BA3182 showed a confirmed partial response (cPR) at 0.6 mg in intrahepatic cholangiocarcinoma with >6 months without progression and prolonged tumor control at doses ≥0.6 mg. Safety was manageable: only 2 cytokine release syndrome events and reversible, transient liver analyte elevations; dose escalation continues and the maximally tolerated dose is not yet defined.
BioAtla (NASDAQ: BCAB) announced clinical data for its AXL-targeting ADC mecbotamab vedotin (BA3011) will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, Nov 5-9, 2025, at National Harbor, MD.
The presentation by Dr. Mihaela Druta on Nov 7, 2025 reports a median overall survival (OS) of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma (abstract #523). Poster session timing to be announced; slides will be posted in the company Publication section after the presentation.
BioAtla (NASDAQ:BCAB) has received FDA alignment on the Phase 3 trial design for ozuriftamab vedotin (Oz-V) in treating Oropharyngeal Squamous Cell Carcinoma (OPSCC). The trial will involve approximately 300 patients randomized between Oz-V and investigator's choice of standard treatments.
The company's Phase 2 trial demonstrated promising results with an overall response rate of 45% and median overall survival of 11.6 months, significantly outperforming current treatments which show only 0-3.4% response rates and 4.4 months median survival. The Phase 3 study design includes potential for accelerated approval based on response rate improvements, with full approval contingent on overall survival benefits.
BioAtla plans to initiate the Phase 3 study with a strategic partner in early 2026 and maintains guidance for completing a strategic partnership for one of its advanced clinical assets this year.
BioAtla (NASDAQ:BCAB) reported Q2 2025 financial results and clinical progress updates. The company's Phase 1 CAB-EpCAM x CAB-CD3 bispecific T-cell engager (BA3182) showed promising results with seven patients achieving tumor size reductions ranging from -5% to -25%. Their Fast Track Designated ozuriftamab vedotin (Oz-V) demonstrated strong efficacy in HPV+ head and neck cancer with a 45% overall response rate and 100% disease control rate.
Financial results showed R&D expenses decreased to $13.7M from $16.2M year-over-year, while net loss improved to $18.7M from $21.1M. The company ended Q2 with $18.2M in cash, down from $49.0M at 2024 year-end, and expects decreased quarterly cash burn as Phase 2 trials conclude. BioAtla remains confident in closing at least one partnership transaction in 2025.
BioAtla (Nasdaq: BCAB), a clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has scheduled its Q2 2025 earnings conference call for August 7, 2025, at 4:30 p.m. ET.
The company will discuss financial results for the quarter ended June 30, 2025, and provide business updates. The earnings release will be available on the company's website before the call. Investors can access the call through the provided domestic and international dial-in numbers or via webcast.
FAQ
What is the current stock price of Bioatla (BCAB)?
What is the market cap of Bioatla (BCAB)?
